Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Melphalan
Drug ID BADD_D01376
Description An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen.
Indications and Usage For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.
Marketing Status Prescription; Discontinued
ATC Code L01AA03
DrugBank ID DB01042
KEGG ID D00369
MeSH ID D008558
PubChem ID 460612
TTD Drug ID D00FGO
NDC Product Code 68152-109; 71052-158; 52609-0001; 68554-0076; 50683-0385; 72893-001; 43744-361; 76055-0021; 72969-046
Synonyms Melphalan | L-PAM | Phenylalanine Mustard | Mustard, Phenylalanine | 4-(Bis(2-chloroethyl)amino)phenylalanine | Medphalan | Sarkolysin | Sarcolysine | Merphalan | Alkeran
Chemical Information
Molecular Formula C13H18Cl2N2O2
CAS Registry Number 148-82-3
SMILES C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Chromosomal abnormalities and abnormal gene carriersTribbles homolog 3Q96RU7Not Available11359799; 12649745; 10843675
InjuryT-lymphocyte activation antigen CD80P33681T5823811359799; 12649745; 10843675
InjuryElongator complex protein 1O95163T4988811359799; 12649745; 10843675
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Impaired healing08.03.02.001--Not Available
Infection11.01.08.0020.001066%Not Available
Infertility21.03.02.001--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Iris adhesions06.06.06.0030.000799%Not Available
Iris atrophy06.06.06.0040.000533%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lenticular opacities06.06.01.0030.000533%Not Available
Leukaemia16.01.03.001; 01.10.03.001--
Leukopenia01.02.02.0010.000533%Not Available
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Local reaction08.01.03.012--Not Available
Loss of consciousness17.02.04.0040.000533%Not Available
Lung disorder22.02.07.0010.000139%Not Available
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Mucosal inflammation08.01.06.0020.001332%Not Available
Muscle atrophy17.05.03.004; 15.05.03.003--Not Available
Muscle injury15.05.07.001; 12.01.07.002--Not Available
Muscle necrosis15.05.05.007--Not Available
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Neoplasm malignant16.16.01.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.0040.001066%Not Available
Non-Hodgkin's lymphoma01.17.01.001; 16.35.01.001--Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages